The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents

Zhang,Chengcheng Christine; Gdynia,Georg; Ehemann,Volker; Roth,Wilfried

doi:10.3892/ijo.2014.2785

The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents

Authors:
- Chengcheng Christine Zhang
- Georg Gdynia
- Volker Ehemann
- Wilfried Roth
View Affiliations

Affiliations: Molecular Tumor Pathology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany, Institute of Pathology, University of Heidelberg, Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany
Published online on: December 1, 2014 https://doi.org/10.3892/ijo.2014.2785
Pages: 667-676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The HMGB1 protein has multiple functions in tumor biology and can act both as a transcription factor and as a cytokine. HMGB1 is released during cell death, and in our previous studies we demonstrated that HMGB1 induces a distinct, necrosis-like cell death in glioblastoma. In epithelial malignant tumors such as colorectal cancer (CRC), the HMGB1-dependent effects show cross-talk with apoptotic signal transduction. Treatment of CRC cells with low concentrations of recombinant HMGB1 results in dose-dependent cytotoxicity which is morphologically characterized by the formation of giant mitochondria and does not share features of apoptosis. HMGB1-triggered cell death is associated with intracellular ROS release, and overexpression of Bcl-2 blocks both the increase of ROS as well as HMGB1-dependent cell death. Importantly, treatment with recombinant HMGB1 or overexpression of endogenous HMGB1 strongly sensitizes CRC cells to the cytotoxic activity of the pro-apoptotic death ligand TRAIL as well as the small molecule Bcl-2 family inhibitor ABT‑737. Moreover, treatment of CRC cells with TRAIL or ABT‑737 induces a release of endogenous HMGB1 into the extracellular space, and preincubation with glycyrrhizin, an HMGB1 inhibitor, significantly inhibits induction of cell death by TRAIL and ABT‑737, suggesting that HMGB1 functionally contributes to the execution of cell death triggered by pro-apoptotic agents. Finally, we investigated the expression of HMGB1 in human CRC tumor samples and found that loss of HMGB1 expression is associated with a more aggressive phenotype and a more advanced stage of disease in patients with CRC. Altogether, our findings demonstrate a functional link between cytotoxic signaling cascades triggered by HMGB1 and pro-apoptotic agents leading to an HMGB1-dependent sensitization to CRC cell death. Thus, a further evaluation of recombinant HMGB1 as part of an experimental combination treatment of CRC seems warranted.

View Figures

View References

1	Muller S, Scaffidi P, Degryse B, et al: New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20:4337–4340. 2001. View Article : Google Scholar
2	Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
3	Shirakawa H, Tsuda K and Yoshida M: Primary structure of non-histone chromosomal protein HMG2 revealed by the nucleotide sequence. Biochemistry. 29:4419–4423. 1990. View Article : Google Scholar : PubMed/NCBI
4	Bustin M: Chromatin unfolding and activation by HMGN(^*) chromosomal proteins. Trends Biochem Sci. 26:431–437. 2001. View Article : Google Scholar : PubMed/NCBI
5	Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–251. 1999. View Article : Google Scholar : PubMed/NCBI
6	Andersson U, Wang H, Palmblad K, et al: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 192:565–570. 2000. View Article : Google Scholar : PubMed/NCBI
7	Zhang XD, Gillespie SK, Borrow JM and Hersey P: The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 3:425–435. 2004.PubMed/NCBI
8	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
9	Bell CW, Jiang W, Reich CF III and Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 291:C1318–C1325. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wang H, Yang H, Czura CJ, Sama AE and Tracey KJ: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med. 164:1768–1773. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wang H, Ward MF and Sama AE: Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock. 32:348–357. 2009. View Article : Google Scholar : PubMed/NCBI
12	Yang H, Wang H, Czura CJ and Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol. 78:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
13	Bianchi ME: HMGB1 loves company. J Leukoc Biol. 86:573–576. 2009. View Article : Google Scholar : PubMed/NCBI
14	Taniguchi N, Kawahara K, Yone K, et al: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48:971–981. 2003. View Article : Google Scholar : PubMed/NCBI
15	Dumitriu IE, Baruah P, Valentinis B, et al: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 174:7506–7515. 2005. View Article : Google Scholar : PubMed/NCBI
16	Gdynia G, Keith M, Kopitz J, et al: Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria. Cancer Res. 70:8558–8568. 2010. View Article : Google Scholar : PubMed/NCBI
17	Gillies RJ, Didier N and Denton M: Determination of cell number in monolayer cultures. Anal Biochem. 159:109–113. 1986. View Article : Google Scholar : PubMed/NCBI
18	Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:271–279. 1991. View Article : Google Scholar : PubMed/NCBI
19	Ehemann V, Sykora J, Vera-Delgado J, Lange A and Otto HF: Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett. 194:125–131. 2003. View Article : Google Scholar : PubMed/NCBI
20	Ehemann V, Kern MA, Breinig M, et al: Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int J Cancer. 122:2719–2725. 2008. View Article : Google Scholar : PubMed/NCBI
21	Webb J: Effect of more than one inhibitor. Enzyme Metabolic Inhibitors. 1:488–512. 1963.
22	Ulloa L, Ochani M, Yang H, et al: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA. 99:12351–12356. 2002. View Article : Google Scholar : PubMed/NCBI
23	Mollica L, De Marchis F, Spitaleri A, et al: Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 14:431–441. 2007. View Article : Google Scholar : PubMed/NCBI
24	Krishna S, Low IC and Pervaiz S: Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2. Biochem J. 435:545–551. 2011. View Article : Google Scholar : PubMed/NCBI
25	Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
26	Tagscherer KE, Fassl A, Campos B, et al: Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 27:6646–6656. 2008. View Article : Google Scholar : PubMed/NCBI
27	Kroemer G, Galluzzi L, Vandenabeele P, et al: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 16:3–11. 2009. View Article : Google Scholar :
28	Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:239–257. 1972. View Article : Google Scholar : PubMed/NCBI
29	Girard JP: A direct inhibitor of HMGB1 cytokine. Chem Biol. 14:345–347. 2007. View Article : Google Scholar : PubMed/NCBI
30	Chen ZX and Pervaiz S: Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death Differ. 14:1617–1627. 2007. View Article : Google Scholar : PubMed/NCBI
31	Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL and Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 75:241–251. 1993. View Article : Google Scholar : PubMed/NCBI
32	Huang JC, Zamble DB, Reardon JT, Lippard SJ and Sancar A: HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA. 91:10394–10398. 1994. View Article : Google Scholar : PubMed/NCBI
33	Wei M, Burenkova O and Lippard SJ: Cisplatin sensitivity in Hmbg1^−/− and Hmbg1^+/+ mouse cells. J Biol Chem. 278:1769–1773. 2003. View Article : Google Scholar
34	Matsui S, Matsumoto H, Sonoda Y, et al: Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol. 4:1633–1644. 2004. View Article : Google Scholar : PubMed/NCBI
35	Nagai T, Egashira T, Yamanaka Y and Kohno M: The protective effect of glycyrrhizin against injury of the liver caused by ischemia-reperfusion. Arch Environ Contam Toxicol. 20:432–436. 1991. View Article : Google Scholar : PubMed/NCBI
36	Kim DE, Youn YC, Kim YK, Hong KM and Lee CS: Glycyrrhizin prevents 7-ketocholesterol toxicity against differentiated PC12 cells by suppressing mitochondrial membrane permeability change. Neurochem Res. 34:1433–1442. 2009. View Article : Google Scholar : PubMed/NCBI
37	Nestl A, Von Stein OD, Zatloukal K, et al: Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 61:1569–1577. 2001.PubMed/NCBI
38	Fedele M, Bandiera A, Chiappetta G, et al: Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res. 56:1896–1901. 1996.PubMed/NCBI
39	Leman ES, Madigan MC, Brunagel G, Takaha N, Coffey DS and Getzenberg RH: Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. J Cell Biochem. 88:599–608. 2003. View Article : Google Scholar : PubMed/NCBI
40	Kuniyasu H, Chihara Y, Kondo H, Ohmori H and Ukai R: Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep. 10:1863–1868. 2003.PubMed/NCBI
41	Ram TG, Reeves R and Hosick HL: Elevated high mobility group-I(Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells. Cancer Res. 53:2655–2660. 1993.PubMed/NCBI
42	Bussemakers MJ, van de Ven WJ, Debruyne FM and Schalken JA: Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res. 51:606–611. 1991.PubMed/NCBI
43	Dolde CE, Mukherjee M, Cho C and Resar LM: HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat. 71:181–191. 2002. View Article : Google Scholar : PubMed/NCBI
44	Kuniyasu H, Sasaki T, Sasahira T, Ohmori H and Takahashi T: Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology. 71:129–136. 2004. View Article : Google Scholar : PubMed/NCBI
45	Peng RQ, Wu XJ, Ding Y, et al: Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO⁺ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer. 10:4962010. View Article : Google Scholar
46	Volp K, Brezniceanu ML, Bosser S, et al: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 55:234–242. 2006. View Article : Google Scholar
47	Kusume A, Sasahira T, Luo Y, et al: Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology. 76:155–162. 2009. View Article : Google Scholar : PubMed/NCBI
48	Apetoh L, Ghiringhelli F, Tesniere A, et al: The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 220:47–59. 2007. View Article : Google Scholar : PubMed/NCBI
49	Apetoh L, Ghiringhelli F, Tesniere A, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13:1050–1059. 2007. View Article : Google Scholar : PubMed/NCBI
50	Tesniere A, Schlemmer F, Boige V, et al: Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 29:482–491. 2010. View Article : Google Scholar
51	Lim B, Scicchitano A, Beachler C, et al: FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 14:711–719. 2013. View Article : Google Scholar : PubMed/NCBI
52	Duiker EW, Mom CH, de Jong S, et al: The clinical trail of TRAIL. Eur J Cancer. 42:2233–2240. 2006. View Article : Google Scholar : PubMed/NCBI
53	Balakrishnan K and Gandhi V: Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 31:1384–1394. 2013. View Article : Google Scholar : PubMed/NCBI